wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q42378535-4DA40573-94DC-40F8-8C43-E018C1585D09
Q42378535-4DA40573-94DC-40F8-8C43-E018C1585D09
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42378535-4DA40573-94DC-40F8-8C43-E018C1585D09
The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.
P2860
Q42378535-4DA40573-94DC-40F8-8C43-E018C1585D09
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42378535-4DA40573-94DC-40F8-8C43-E018C1585D09
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e4a1aefd6447fd732c00365ae6b8d2d03ca49d2d
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.